European Nuclear Medicine/Radiopharmaceuticals Market worth $1.62 Billion by 2020

1
MarketsandMarkets Presents
European Nuclear Medicine/Radiopharmaceuticals
Market worth 1.62 Billion by 2020

http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
2
The report European Nuclear Medicine/Radiopharmac
euticals Market by Type (Diagnostic (SPECT -
Technetium, PET - F-18), Therapeutic (Beta
Emitters - I-131, Alpha Emitters, Brachytherapy -
Y-90)), by Application (Oncology, Thyroid,
Cardiology) - Forecasts to 2020, analyzes and
studies the major market drivers, restraints,
challenges, and opportunities. Browse 145 market
data tables and 60 figures spread through 195
pages and in-depth TOC on European Nuclear
Medicine/Radiopharmaceuticals Market by Type
(Diagnostic (SPECT - Technetium, PET - F-18),
Therapeutic (Beta Emitters - I-131, Alpha
Emitters, Brachytherapy - Y-90)), by Application
(Oncology, Thyroid, Cardiology) - Forecasts to
2020 http//www.marketsandmarkets.com/Market-Rep
orts/european-nuclear-medicine-radiopharmaceutical
s-market-1107.html
 
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
3
Early buyers will receive 10 customization on
this report.

 
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
4

• This report studies the European nuclear
  medicine/radiopharmaceuticals market for the
  forecast period of 2015 to 2020. This market is
  expected to reach 1.62 Billion by 2020 from
  1.09 Billion in 2015, at a CAGR of 8.2 during
  the forecast period (2015 to 2020).
• The European nuclear medicine/radiopharmaceuticals
  market is segmented on the basis of type,
  application, and country.

http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
5

• Based on type, the European nuclear
  medicine/radiopharmaceuticals market is
  categorized into diagnostic and therapeutic
  radioisotopes. In 2015, the diagnostic segment
  accounts for a major share of the European
  nuclear medicine/radiopharmaceuticals market. The
  diagnostic radiopharmaceuticals market is further
  segmented into SPECT and PET radioisotopes. In
  2015, the SPECT segment accounts for the largest
  share of the European nuclear medicine/radiopharma
  ceuticals diagnostic market. The therapeutic
  radiopharmaceuticals market is further segmented
  into beta emitters, alpha emitters, and
  brachytherapy. In 2015, the beta emitters segment
  accounts for the largest share of the European
  nuclear medicine/radiopharmaceuticals therapeutic
  market.

http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
6

• Based on application, the European nuclear
  medicine/radiopharmaceuticals market is segmented
  into SPECT, PET, and therapeutic applications. In
  2015, the cardiology application accounts for the
  largest share of European nuclear medicine SPECT
  market. The PET market is dominated by oncology
  applications and therapeutic market is dominated
  by thyroid applications.

http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
7

• On the basis of country, the market is divided
  into Germany, France, Italy, U.K., Spain, Russia,
  and the Rest of Europe (RoE). The Rest of Europe
  comprises Sweden, Switzerland, Poland, Denmark,
  The Netherlands, and Belgium, among others. In
  2015, Germany accounts for the largest share of
  the European nuclear medicine/radiopharmaceuticals
  market, followed by France, Italy, and U.K.

http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
8

• Factors such as increasing preference for SPECT
  and PET scans, advances in radiotracers, advent
  of alpha radio immunotherapy-based targeted
  cancer treatment, increasing incidence
  mortality rate of cancer and cardiac ailments are
  driving the growth of this market. However,
  factors such as shorter half-life of
  radiopharmaceuticals, competition from
  conventional diagnostic procedures are hindering
  the growth of this market.

http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
9

• Some of the major players in the European nuclear
  medicine market include Cardinal Health Inc.
  (U.S.), GE Healthcare (U.K.), Bracco Imaging
  S.p.A (Italy), Eczacibasi-Monrol Nuclear Products
  (Turkey), Nordion, Inc. (Canada), Advanced
  Accelerator Applications S.A. (France), Bayer
  Healthcare (Germany), Lantheus Medical Imaging,
  Inc. (U.S.), IBA Molecular Imaging (Belgium), and
  Mallinckrodt plc (Ireland).

http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
10
Contact Us
Contact Mr. Rohan Markets and Markets UNIT no
802, Tower no. 7, SEZ Magarpatta city,
Hadapsar Pune, Maharashtra 411013,
India 1-888-600-6441 Email sales_at_marketsandmarket
s.com
http//www.linkedin.com/company/marketsandmarkets
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
11
About MarketsandMarkets
MarketsandMarkets is the global market research
and consulting company based in the U.S. We
publish strategically analyzed market research
reports and serve as a business intelligence
partner to Fortune 500 companies across the
world. MMs flagship competitive intelligence
and market research platform, "RT" connects over
200,000 markets and entire value chains for
deeper understanding of the unmet insights along
with market sizing and forecasts of niche
markets. The new included chapters on Methodology
and Benchmarking presented with high quality
analytical infographics in our reports gives
complete visibility of how the numbers have been
arrived and defend the accuracy of the
numbers. We at MarketsandMarkets are inspired
to help our clients grow by providing apt
business insight with our huge market
intelligence repository.
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html